How to interpret the Oncotype DX® test results

For your patients with HR+, HER2-, early-stage, invasive breast cancer

The Oncotype DX Breast Recurrence Score® report provides three pieces of information to guide adjuvant chemotherapy treatment decisions for node-negative and node-positive, hormone receptor-positive, HER2-negative, early-stage breast cancer patients.

3 pieces of information provided by the test

1

The Recurrence Score® result

This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score result is used to predict the risk of the breast cancer returning at a distant site, distant recurrence and whether chemotherapy may help reduce the risk.1–6

2

Distant recurrence risk at 9 yearsa

This percentage shows the individualized risk of distant recurrence within 9 years based on the Recurrence Score result when treated with hormonal therapy alone for 5 years.1,4-5

3

Group average absolute chemotherapy benefita

This percentage indicates the benefit expected from adding chemotherapy to hormonal therapy in order to reduce the risk of breast cancer recurrence or death for the Recurrence Score risk group.2-3,4,6

a These results are valid in HR+, HER2-, early-stage, invasive breast cancer patients treated with 5 years of endocrine therapy.

Explore the patient reports

Further Understanding the Results: Node-Negative Patients

The Recurrence Score Result

The majority of patients with a Recurrence Score result of 0-25 do not benefit from the addition of chemotherapy to endocrine therapy.2–4

An important minority of patients with Recurrence Score results 26–100 benefit from the addition of chemotherapy to endocrine therapy.2,3

Further Understanding the Results: Node-Positive Patients

Recurrence Score Result

Patients with a Recurrence Score result of 0–17 do not benefit from the addition of chemotherapy to endocrine therapy.6–9

Patients with a Recurrence Score result of 18–30 can derive a potential benefit from the addition of chemotherapy to endocrine therapy.6,9

Patients with a Recurrence Score result 31-100 benefit from the addition of chemotherapy to endocrine therapy.6

Support Materials

Download clinician-to-patient discussion guides


START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
1 2 3
ABBREVIATIONS
CT = chemotherapy
ER = oestrogen receptor
ET = endocrine therapy
HER2 = human epidermal growth factor receptor 2
TAM = tamoxifen
N1 = node-positive
REFERENCES
  1. Paik et al. N Engl J Med. 2004.
  2. Paik et al. J Clin Oncol. 2006.
  3. Geyer et al. NPJ Breast Cancer. 2018.
  4. Sparano et al. N Engl J Med. 2018.
  5. Dowsett et al. J Clin Oncol. 2010.
  6. Albain et al. Lancet Oncol. 2010.
  7. Stemmer et al. NPJ Breast Cancer. 2017.
  8. Hortobagyi et al. SABCS. 2018.
  9. Nitz et al. Breast Cancer Res Treat. 2017.
Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.™